for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Santen Pharmaceutical Co Ltd

4536.T

Latest Trade

1,928.00JPY

Change

25.00(+1.31%)

Volume

1,228,600

Today's Range

1,896.00

 - 

1,939.00

52 Week Range

1,450.00

 - 

1,988.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,903.00
Open
1,914.00
Volume
1,228,600
3M AVG Volume
21.69
Today's High
1,939.00
Today's Low
1,896.00
52 Week High
1,988.00
52 Week Low
1,450.00
Shares Out (MIL)
399.18
Market Cap (MIL)
760,903.30
Forward P/E
27.34
Dividend (Yield %)
1.37

Next Event

Dividend For 4536.T - 13.0000 JPY

Latest Developments

More

Santen Pharmaceutical Will Enter The Indian Market This Year - Nikkei

Santen Pharmaceutical To Buy Back Up To 2 Percent Of Its Shares Worth 14 Billion Yen Through March 22

PeptiDream announces drug discovery and development agreement with Santen Pharmaceutical

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Santen Pharmaceutical Co Ltd

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

Industry

Biotechnology & Drugs

Contact Info

3-9-19, Shimo-Shinjo, Higashiyodogawa-ku

+81.6.63217000

http://www.santen.co.jp/

Executive Leadership

Akira Kurokawa

Chairman of the Board, Chief Executive Officer, Representative Director

Shigeo Taniuchi

President, Chief Operating Officer, Representative Director

Kazuo Koshiji

Chief Financial Officer, Managing Executive Officer, Chief Director of Finance & Administration

Noriaki Yamamoto

Chief Information Officer, Executive Officer, Chief Director of Information System

Naveed Shams

Chief Scientific Officer, Managing Executive Officer, Chief Director of Research & Development

Key Stats

2.45 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.2K

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (JPY)

2017

56.200

2018

86.730

2019

78.670

2020(E)

69.602
Price To Earnings (TTM)
24.51
Price To Sales (TTM)
3.21
Price To Book (MRQ)
2.64
Price To Cash Flow (TTM)
17.36
Total Debt To Equity (MRQ)
15.28
LT Debt To Equity (MRQ)
10.47
Return on Investment (TTM)
9.54
Return on Equity (TTM)
8.23

Latest News

BRIEF-Aequus Pharmaceuticals enters into agreement with Santen Pharmaceutical's unit

* Has entered into an exclusive agreement in Canada with a unit of Santen Pharmaceutical

BRIEF-Santen Pharmaceutical repurchases shares at 12.31 bln yen

* Says it repurchased 8,284,000 shares of its common stock, at the price of 12.31 billion yen in total, as of Nov. 22

BRIEF-Santen Pharmaceutical to buy back up to 8,284,000 shares for up to 13 bln yen

* Says it to buy back up to 8,284,000 ordinary shares (2 percent stake), from Sep. 13 to Nov. 30

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up